The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes
Open accessAbstract
As part of our effort to increase survival of drug candidates and to move our medicinal chemistry design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) molecules. We carried out a thorough analysis of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates. In particular, we focused on understanding the relationships between physicochemical properties, in vitro ADME (absorption, distribution, metabolism, and elimination) attributes, primary pharmacology binding efficiencies, and in vitro safety data for these two sets of compounds. This scholarship provides guidance for the design of CNS molecules in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Ertl, P., Rohde, B., & Selzer, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,084
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Medicinal chemical properties of successful central nervous system drugs
Pajouhesh, H., & Lenz, G. R. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.541 · Cited by 1,535
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationStructure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 698
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
The impact of drug-induced QT interval prolongation on drug discovery and development
Fermini, B., & Fossa, A. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1108 · Cited by 492
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Self-citationTime-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ligand efficiency indices for effective drug discovery
Abad-Zapatero, C. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.469 · Cited by 279
A review of the metabolism and pharmacokinetics of paroxetine in man
Kaye, C. M., Haddock, R. E., Langley, P. F., Mellows, G., Tasker, T. C. G., Zussman, B. D., & Greb, W. H. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07176.x · Cited by 268
Lipophilicity in PK design: methyl, ethyl, futile
van de Waterbeemd, H., Smith, D. A., & Jones, B. C. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008192010023 · Cited by 244
Application of hydrogen bonding calculations in property based drug design
Abraham, M. H., Ibrahim, A., Zissimos, A. M., Zhao, Y. H., Comer, J., & Reynolds, D. P. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02478-9 · Cited by 180
Fragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
The evolution of synthetic oral drug properties
Proudfoot, J. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.024 · Cited by 129
Understanding mechanisms of toxicity: Insights from drug discovery research
Houck, K. A., & Kavlock, R. J. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.10.022 · Cited by 112
Drug-like properties: guiding principles for design – or chemical prejudice?
Leeson, P. D., Davis, A. M., & Steele, J. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.005 · Cited by 82
In Silico Modeling of Nonspecific Binding to Human Liver Microsomes
Gao, H., Yao, L., Mathieu, H. W., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020131 · Cited by 66
Capter 11 Filtering in Drug Discovery
Lipinski, C. A. (2005) · Annual reports in computational chemistry · doi:10.1016/s1574-1400(05)01011-x · Cited by 49
Walum, E., Hedander, J., & Garberg, P. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.01.056 · Cited by 20
Cited by
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Metadata
- Authors
- Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-03-25
- Volume
- 1
- Issue
- 6
- Pages
- 420-434
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2030215451
- Cited by
- 477
- References
- 28
- FWCI
- 31.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
